ADMA Biologics Inc. Daily Stock Analysis

Daily Stock Analysis, ADMA, ADMA Biologics Inc, priceseries

ADMA Biologics Inc. Daily Stock Analysis
Stock Information
Open
1.62
Close
1.67
High
1.70
Low
1.61
Previous Close
1.63
Daily Price Gain
0.04
YTD High
1.75
YTD High Date
Feb 10, 2022
YTD Low
1.26
YTD Low Date
Jan 13, 2022
YTD Price Change
0.20
YTD Gain
13.61%
52 Week High
2.63
52 Week High Date
Apr 28, 2021
52 Week Low
1.01
52 Week Low Date
Oct 21, 2021
52 Week Price Change
-0.37
52 Week Gain
-18.14%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 13. 2017
2.48
Nov 29. 2017
2.98
11 Trading Days
20.32%
Link
LONG
Dec 22. 2017
2.64
Jan 31. 2018
3.64
25 Trading Days
37.82%
Link
LONG
Jul 19. 2018
4.81
Aug 13. 2018
6.11
17 Trading Days
27.01%
Link
LONG
Jan 3. 2019
2.81
Jan 23. 2019
3.29
13 Trading Days
17.15%
Link
LONG
Feb 12. 2019
3.48
Mar 6. 2019
3.96
15 Trading Days
13.90%
Link
LONG
Mar 29. 2019
3.79
Apr 15. 2019
4.68
11 Trading Days
23.39%
Link
LONG
Aug 12. 2019
3.71
Sep 4. 2019
4.14
16 Trading Days
11.58%
Link
LONG
Sep 5. 2019
4.38
Sep 24. 2019
5.02
13 Trading Days
14.67%
Link
LONG
Oct 15. 2019
4.17
Nov 7. 2019
4.80
17 Trading Days
15.11%
Link
LONG
Jul 15. 2020
2.90
Jul 22. 2020
3.05
5 Trading Days
5.23%
Link
LONG
Jul 30. 2020
3.74
Jul 31. 2020
3.94
1 Trading Days
5.21%
Link
LONG
Apr 21. 2021
1.74
May 3. 2021
1.91
8 Trading Days
10.13%
Link
LONG
Oct 21. 2021
1.21
Nov 18. 2021
1.49
20 Trading Days
23.21%
Link
LONG
Jan 31. 2022
1.45
Feb 18. 2022
1.58
14 Trading Days
9.16%
Link
Company Information
Stock Symbol
ADMA
Exchange
NasdaqCM
Company URL
http://www.admabiologics.com
Company Phone
(201) 478-5552
CEO
Adam S. Grossman
Headquarters
New Jersey
Business Address
C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ 07446
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001368514
About

ADMA Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of human plasma and plasma-derived therapeutics. It operates through the Plasma Collection Center and Research and Development segments. The Plasma Collection Center segment comprises of operations in Georgia. The Research and Development segment involves plasma development operations in New Jersey. The company's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Description

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading